Tumor subtype-specific transcriptional signatures predict recurrence risk in hepatocellular carcinoma.
This approach establishes a biologically informed framework for stratifying recurrence risk based on RNA-seq data, potentially enhancing riskadapted surveillance and postoperative management for HCC.